Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Early Treatment With Interferon Beta-1b Can Delay Progression Of Multiple Sclerosis

03.08.2007
Early treatment of multiple sclerosis (MS) patients with interferon beta-1b can prevent the disabling development of the condition, conclude authors of an Article published in this week’s edition of The Lancet.

Professor Ludwig Kappos University Hospital Petersgraben, Basle, Switzerland, and colleagues, as part of the BENEFIT study, did a study of 468 patients who had shown early symptoms of MS. Of these, 292 were randomised to receive 250µg interferon beta-1b and 176 to receive placebo, subcutaneously every other day for two years, or until they were diagnosed with clinically definite multiple sclerosis (CDMS). After diagnosis of CDMS or completion of two-years of treatment, the patients were then eligible to enter a follow-up phase to receive interferon beta-1b treatment.

Of the patients originally enrolled, 89% entered the follow-up phase, while 84% completed the three-years post-randomisation follow up (2 years in initial phase, one year follow up phase). The study measured patients’ disability status using the expanded disability status scale (EDSS) and found that early treatment with interferon beta-1b reduced the risk for progression of disability by 40% compared with delayed treatment. And whilst 51% of patients in the delayed-treatment group developed CDMS, only 37% of the patients who received early treatment with interferon beta-1b developed CDMS. Thus early treatment reduced the risk of developing CDMS by 41%.

The authors conclude: “Our data suggest that early initiation of treatment with interferon-1b prevents the development of confirmed disability, supporting its use after the first manifestation of relapsing-remitting MS.”

In an accompanying Comment, Dr Sean Pittock, Mayo Clinic of Medicine, Rochester, Minnesota, USA, says: “Kappos and colleagues have set a new standard against which future extension trials will be compared.”

He concludes: “The results should, however, be interpreted with care because the magnitude of benefit, although significant, is clinically small. This follow-up should not be misconstrued as evidence for a treat all approach.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/ms.pdf

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>